At close of market on Monday, Prometic Life Sciences Inc. (TSX:PLI) stock finished trading at -14.29%, bringing the stock price to $0.06 on the Toronto Stock Exchange. The stock price saw a low of $0.06 and a high of $0.07.
The company’s stock was traded 467 times with a total of 8,199,443 shares traded.
Prometic Life Sciences Inc. has a market cap of $1.24 billion, with 20.72 billion shares in issue.
Prometic Life Sciences Inc is a global biopharmaceutical corporation supplying technologies for Bioseparations while also developing its own orphan drugs, plasma-derived therapeutics and small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. The company also offers drug purification of biologics, drug development, proteomics and the elimination of pathogens. The company’s segments consist of the Small molecule therapeutics segment, the Plasma-derived therapeutics segment and the Bioseparations segment. Majority of the revenue is derived from the Small molecule therapeutics segment that develops drug candidates for rare or orphan indications.
